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Abstract
It has been observed that both cancer tissue cells and normal proliferating cells (NPCs) have the 
Warburg effect. Our goal here is to demonstrate that they do this for different reasons. To accomplish 
this, we have analyzed the transcriptomic data of over 7000 cancer and control tissues of 14 cancer 
types in TCGA and data of five NPC types in GEO. Our analyses reveal that NPCs accumulate large 
quantities of ATPs produced by the respiration process before starting the Warburg effect, to raise the 
intracellular pH from ~6.8 to ~7.2 and to prepare for cell division energetically. Once cell cycle starts, the 
cells start to rely on glycolysis for ATP generation followed by ATP hydrolysis and lactic acid release, to 
maintain the elevated intracellular pH as needed by cell division since together the three processes are 
pH neutral. The cells go back to the normal respiration-based ATP production once the cell division 
phase ends. In comparison, cancer cells have reached their intracellular pH at ~7.4 from top down as 
multiple acid-loading transporters are up-regulated and most acid-extruding ones except for lactic acid 
exporters are repressed. Cancer cells use continuous glycolysis for ATP production as way to acidify the 
intracellular space since the lactic acid secretion is decoupled from glycolysis-based ATP generation and 
is pH balanced by increased expressions of acid-loading transporters. Co-expression analyses suggest 
that lactic acid secretion is regulated by external, non-pH related signals. Overall, our data strongly 
suggest that the two cell types have the Warburg effect for very different reasons. 
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Introduction
Otto Warburg published his seminal paper in 1927 on the observation that cancer cells tend to allocate 
substantial fractions of glucose to glycolytic ATP production followed by lactate generation rather than 
by the TCA cycle and the respiration chain regardless of the O2 level, which is referred to as the Warburg 
effect [1] and serves as the basis for PET/CT based cancer detection. This observation has perplexed 
generations of cancer researchers, since the respiration pathway is considerably more efficient for ATP 
generation than glycolysis, with the former producing 36 ATPs and the latter producing 2 ATPs per 
glucose. Multiple hypotheses have been put forward about why cancer cells do this as follows. (1) 
Cancer cells may have dysfunctional mitochondria, which was later proved to be incorrect [2−4]. (2) The 
glycolytic pathway is faster than the respiration pathway for synthesizing the same number of ATPs from 
glucose, hence selected to support the rapid cell proliferation in cancer [5]; but this view is challenged as 
ATP is shown to be not a rate-limiting factor in cancer proliferation [6]. (3) Cancer cells have reduced 
mitochondrial activities due to hypoxia, partially because of the increased generation of reactive oxygen 
species (ROS) [7] and nitric oxide production [8]; however, cancer cells are known to have respiration 
activities across different cancer types and high levels of such activities are reported in some cancers [9]. 
(4) Cancer cells are lack of NAD+, hence using the conversion of pyruvate to lactate for NAD+ production 
[5], which was argued against since most of the relevant carbons were excreted, hence there is no net 
NAD+ production [10]. And (5) Warburg effect is a common characteristic of all proliferating cells, 
including cancer cells and NPCs [5]. While other hypotheses are largely considered as unacceptable [11], 
the last one has gained popularity in the past few years [12,13], which we address here. 
We have approached this problem from the perspective of intracellular acid-base homeostasis. It is 
known that healthy human epithelial cells have a mildly acidic intracellular pH at ~6.8 and a basic 
extracellular pH at ~7.2, while cancer cells have reversed these pH levels with intracellular pH at 7.2−7.4 
[14] and extracellular pH at 6.6−6.8 [15]. To understand how cancer cells have reversed the intracellular 
and extracellular pH levels, we have examined the gene expression levels of all H+, OH- and HCO3- related 
plasma-membrane transporters across 14 cancer types, which include all the cancer types in the TCGA 
database with sufficiently large numbers (at least 10) of cancer tissues. To our surprise, we note that all 
cancer cells consistently up-regulate the expressions of multiple acid-loading transporters and repress 
the expressions of most acid-extruding transporters except for the lactic acid exporters throughout the 
progression of the cancers examined. This strongly suggests that there must be some unidentified 
metabolic processes that continuously produce alkaline molecules, since that the gradient-driven lactic 
  
acid exporters cannot accomplish the reversal between the intracellular and extracellular pH levels, at 
least not by the transporters alone.
We have recently predicted [16], through mining cancer tissue transcriptomic data and 
mathematical modeling, that cancer cells have Fenton reactions: Fe2+ + H2O2 → Fe3+ +  + OH- in their ∙ OH
cytosol. Fenton reactions result from local iron accumulation and elevated H2O2 concentration due to 
increased local populations of innate immune cells, specifically neutrophil and macrophages. We predict 
that cancer cells of all the 14 cancer types examined have such reactions persistently using superoxide (
), produced by local innate immune cells and the host cells’ mitochondria, as the key reducing O ∙‒2
element of Fe3+. We have further shown that OH- produced by such reactions would ultimately 
overwhelm the cytosolic pH buffer, and hence drive up the intracellular pH. As response, various 
processes are induced to acidify the intracellular space to maintain the acid-base homeostasis [16]. 
We have predicted that glycolytic ATP synthesis represents a key responding process for acidifying 
the intracellular pH, since glycolytic ATP synthesis is pH neutral, while respiration-based ATP production 
consumes one proton per ATP and hydrolysis of any ATP releases one proton [17]. That is, synthesis of 
each glycolytic ATP releases one net proton when it is consumed while a respiration-synthesized ATP will 
be neutral when the ATP is hydrolyzed. In addition, it is also known that the level of glycolysis correlates 
strongly with the level of the predicted cytosolic Fenton reaction [16]. 
In contrast, NPCs generate ATPs through the respiration pathway and accumulate ATPs before cell 
proliferation. NPCs will partially switch to glycolytic ATP production when sufficiently large numbers of 
ATPs are intracellularly accumulated, hence driving up the intracellular pH as well as preparing for cell 
division energetically. During proliferation, consumption of an ATP leads to the release of a proton, 
coupled with the lactate generated from pyruvate at the end of glycolysis. Therefore, serving two 
purposes, that is, to maintain the raised pH level needed for proliferation and replenish each consumed 
ATP. 
Results
Warburg effects in cancer vs. in activated NPC samples
We have used the following criteria to determine if a cancer tissue (and a NPC sample) has the Warburg 
effect: (i) Expressions of the genes encoding lactate dehydrogenase unit A or B, LDHA or LDHB, and of 
  
the genes encoding the main lactic acid exporters, SLC16A1 or SLC16A3, are considerably up-regulated 
(fold change > 2) in cancer tissue (and activated NPC cells) in comparison to the controls; and (ii) the 
proportion of the glycolytic flux via pyruvate kinase (PK, encoded by PKM) into the TCA cycle via 
pyruvate dehydrogenase (PDH, encoded by PDHB) decreases in cancer tissues (and activated NPC cells) 
in comparison to controls. Here, we use the normalized expression of PDHB against that of PKM as an 
approximation to the fraction of the metabolic efflux out of PK into the TCA cycle via PDH. 
We note that the expression of LDHA is up-regulated in the cancer tissues of all 14 cancer types 
examined except for LIHC (Figure S1). In addition, the expression of either SLC16A1 or SLC16A3 is up-
regulated in the cancer tissues of all 14 cancer types except for COAD (see Materials and Methods for 
definition), which is known to have weak Warburg effect and hence generally not detected via PET/CT. 
In addition, the relative ratio of PDHB/PKM decreases in cancer tissues across different stages in 
comparison to the controls. Similarly, we found increased expression of SLC16A1 and LDHA(or LDHB) in 
all the five NPC types (Figure S2). However, the relative PDHB/PKM ratio is reduced only in CD4+ T cells 
and effector T cells but remains comparable in the other three cell types in comparison to the matched 
controls. Hence, we predict that all the cancer types and the NPCs under consideration have the 
Warburg effect. 
Opposite behaviors of pH-related transporters in cancer vs. NPCs
We have examined the gene expression levels of all the selected pH-related plasma-membrane 
transporters in cancer and in NPCs (see Materials and methods). We now go through the key 
differences between the expression patterns of these genes in groups in cancer vs. NPCs, with the 
detailed comparisons given in Figure 1. Note that in the following, the first three groups of 
genes are acid-loading transporter genes, and the next four are acid-extruding ones.
Acid -loading transporter genes 
Among the acid-loading transporter genes, the expressions of SLC4A1AP, SLC4A2, and SLC4A3 
are up-regulated or remain unaltered in cancer tissues vs. controls across most of the 14 cancer 
types. In comparison, the expressions of these genes are mostly down-regulated or remain 
unchanged across all the NPCs except for SLC4A1AP, which is up-regulated in iPSC. 
  
The expression of SLC26A6 is up-regulated or remains the same in 11 of the 14 cancer types 
except for COAD, KIRC, and KIRP. In comparison, the expression of SLC26A6 is not changed 
in the activated NPC samples vs. controls except for the iPSC samples. 
For the ATP6V genes, we have considered the expressions of ATP6V0B and ATP6V0C since 
their protein products are known to be localized in plasma membrane and have the same 
expression by definition. Table S1 shows the subcellular locations for the ATP6V0 protein 
products predicted by Genecards [18], and Table S2 gives the predicted ATP6V0B expressions in 
both cancers and NPCs. We can see from the table that the gene is up-regulated across all cancer 
types except for KIRC and KIRP; and it has no change or is down-regulated in its expressions 
across all the NPC samples in the activated state vs. the control. 
Acid-extruding transporter genes
Among the four groups of acid-extruding transporter genes, SLC4A4/9 are down-regulated or 
show no changes in their expressions across all cancer types except for PRAD with SLC4A4 
being up-regulated. In comparison, these genes show no changes or are up-regulated in their 
expressions in all the activated NPCs vs. the controls except for iPSC and effector T cell, in 
which SLC4A4 and SLC4A9 are down-regulated, respectively. 
For SLC9A2, 3, 4, 9, they are mostly down-regulated in cancer vs. controls, mostly by 
SLC9A9 and SLC9A2, while majority of these genes show no changes in their expressions in the 
activated NPCs vs. controls. 
SLC26A9 is predominantly down-regulated in cancer, and has no change in NPCs. 
The only group of genes considered here has the same behaviors between cancer vs. NPCs is 
SLC16A1/3, with their expressions up-regulated in both cancer and the activated NPCs. 
In sum, expressions of the acid-loading transporter genes are largely up-regulated, whereas 
expressions of the acid-extruding transporter genes are down-regulated in cancer vs. controls 
except for SLC16A1/3. For the acid-loading transporter genes, NPCs generally show the opposite 
gene-expression patterns to those in cancer while the acid-extruding transporters mostly show no 
changes in their expressions. Hence we conclude that cancer cells use the transporters under 
consideration to acidify their intracellular pH while NPCs alkalinize it. Given that both cancer 
and NPCs have comparable intracellular pH level [14,19], we infer that cancer cells reach their 
pH level from above while NPCs get there from below. 
  
A natural question would be: how can cancer cells maintain a basic intracellular pH when they are 
continuously acidified by powerful transporters? First, we posit that SLC16A1/3 are not the reason since 
they are driven by proton gradients, hence impossible for them to reverse the intracellular and 
extracellular pH. More importantly, there are numerous up-regulated acid-loading transporters with 
comparable expression levels (Figure 1), and multiple such transporters have higher Vmax values than 
SLC16A1/3. For instance, the Vmax of V-ATPase is 3−4 orders of magnitude higher (~40 nmol/min/mg) 
[20] than that of SLC16A1/3 (~63.0 pmol/min/mg) [21]. These data indicate that the acidification rate is 
substantially higher than the alkalinization rate by these transporters. 
Actually cancer tissue cells are known to utilize a number of other metabolic processes to acidify 
their intracellular space. These include: (i) diffusion of fatty acids from blood circulation into cancer cells 
, hence acidifying the intracellular space since their pKa values are approximately 4.5 [22], lower than 
the intracellular pH; (ii) diffusion of NH3 out of cancer cells into blood circulation [23], thus making the 
intracellular pH more acidic, knowing that its pKa is 9.26 [22]; (iii) biosynthesis and deployment of large 
quantities of sialic acids and gangliosides [24], making the intracellular pH more acidic [25]; and (iv) 
glycolytic ATP production (see the next section).
All these data strongly suggest one possibility that there are unknown metabolic processes that 
continuously produce alkaline molecules inside cancer cells, which may have triggered all the above 
processes to continuously acidify the intracellular space to keep the cells viable. 
Fenton reactions in cancer cells and their impact on intracellular pH
We have recently build a computational model based on gene expression data of cancer vs. control 
tissues of all the 14 cancer types examined in this study, to demonstrate that all cancer tissue cells have 
Fenton reactions in their cytosol [16]. We outline the general idea of the study, for readers’ 
convenience.
It has been widely observed that cancer tends to be associated with chronic inflammation 
[26], which will give rise to elevated H2O2 level [27]. In addition, it has also been widely noted 
that cancer tends to have local accumulation of iron [28]. The combination of the two will result 
in an inorganic chemical reaction, called Fenton reaction: Fe2+ + H2O2 → Fe3+ +  + OH-. ∙ OH
Multiple authors have reported the observation of Fenton reactions in cancer across numerous  
  
cancer types [28,29]. In our previous study , we have predicted that cancer cells generally use 
superoxide ( ) as the reducing molecule to convert Fe3+ to Fe2+, produced predominantly by O ∙‒2
local innate immune cells including neutrophil and macrophages [16]. This will lead to persistent 
Fenton reaction, which can be rewritten asO ∙‒2  + H2O2→ ∙ OH + OH ‒ + O2
(also known as Haber-Weiss reaction) with Fe2+ as the catalyst and not consumed, where Fe2+ 
could be in iron-sulfur clusters or labile-iron pool [30]. Essentially, the reaction continuously 
produce  and , fueled by  and  generated predominantly by local immune cells ∙ OH OH ‒ O ∙‒2 H2O2
and catalyzed intracellular Fe2+. 
Knowing that  can only be produced intracellularly by Fenton reactions when cells are ∙ OH
not exposed to radiation [31], we have predicted if a cell harbors Fenton reaction in its cytosol if 
the quantities on two sides of the above chemical reaction strongly correlate with each other, 
given the level of Fe2+, specifically between [ , where [X] ∙ OH] 𝑣𝑠. [H2O2], [O ∙‒2 ] and [Fe2 + ]
represents the quantity of X. The rationale is that (1) we have observed that each of these 
quantities can be reliably estimated using the expressions of selected genes; and (2) the level of 
correlation between the two sides is highly consistent with the level of Fenton reaction [16]. File 
S1 and Table S3 show the statistical correlation between the two sides for all the cancer tissues 
of the 14 cancer types considered in our study [16]. Based on the data, we predict that all the 
cancer tissues have Fenton reactions in their cytosol. 
In addition, we have also shown that Fenton reaction-produced OH- can overwhelm the cytosolic pH 
buffer within a relatively short amount of time [16]. Then a range of processes is triggered to acidify the 
intracellular space, including the transporters under study, thus keeping its pH from becoming too high, 
since changes in intracellular pH can alter the whole biochemistry in a fundamental manner. In 
comparison, we predict that the activated NPCs have no or slight Fenton reactions based on data given 
in Table S4. 
Increased glycolytic ATP production is a response to cytosolic Fenton reactions
To pin down the possible reasons for the observed behaviors of the transporters in the first Results 
section, we searched for genes whose expressions correlate positively with those of the acid-loading 
transporter genes and simultaneously negatively with those of the acid-extruding ones for each cancer 
  
type. Table S5 lists the pathways enriched by such genes for each cancer type, with the detailed 
enrichment procedure given in File S1. Functional analyses reveal that these pathways largely fall into 
four categories: (1) cell proliferation and development; (2) macromolecular damages and degradation; 
(3) immune activities; and (4) stress response. These results point to the possibility that the behaviors of 
the transporters might be relevant to cytosolic Fenton reactions since as we previously shown [16] and 
outlined in the previous section that (i) Fenton reactions are the results of immune response to 
persistent irritations at the disease sites; and (ii) cytosolic Fenton reactions damage intracellular 
macromolecules by their , and drive cell division by the persistent nucleotide synthesis induced as ∙ OH
response to continuous production of OH- [16]. 
Furthermore analyses have revealed that these transporter genes indeed strongly correlate 
genes/pathways used to define cytosolic Fenton reactions as detailed in Table S6 and Figure 2. 
Specifically, as shown in Figure 2, the expressions of proteasome (PSM) genes, one of the three gene 
groups used to define Fenton reaction (see later discussion of this section) positively correlate with 
those of the acid-loading transporter genes and negatively correlate with those of the acid-extruding 
transporter genes across all 14 cancer types. By these and the above paragraph, we predict the 
behaviors of these transporters are related to the OH- produced by Fenton reactions. In contrast, the 
above correlations do not exist for NPC samples, as detailed in Table S7. 
Interestingly, the correlation between PKM and SLC16A1 in cancers is considerably weaker than it 
in NPCs as shown in Figure 3A and Figure S3, hence suggesting that the role of SLC16A1 might be 
different from the other pH-related transporters. 
We now show statistically that glycolytic ATP production is also relevant to cytosolic Fenton 
reactions. To accomplish this, we have calculated correlations between the level of glycolytic ATP 
production as reflected by the expression of PKM and (i) the level of protein damage as reflected by the 
expression of the PSM genes, (ii) the level of iron uptake represented by the expressions of TFRC 
(transferrin receptor) and TFR2, and (iii) the intracellular H2O2 level reflected by the expressions of TXN 
(thioredoxin), TXN2, GCLC (glutamate-cysteine ligase catalyst) and GCLM, respectively, with detailed 
results shown in Figure 3B. Note that the three groups of genes (i – iii) are used for establishing cytosolic 
Fenton reactions [16]. Hence, we conclude that the level of glycolytic ATP production strongly correlates 
with the level of Fenton reaction. 
  
To see how glycolytic ATP production may be relevant to cytosolic pH, we note that the production 
of an ATP by respiration: ADP3- + HPO42- → ATP4- + OH- consumes one proton, while ATP generation by 
glycolysis: glucose + 2ADP3- + 2HPO42- → 2 lactate + 2 ATP4- is pH neutral [17]. And hydrolysis of any ATP: 
ATP4- + H2O → ADP3- + HPO42- + H+ releases one proton. Hence, we conclude that glycolytic ATP 
production generates one net H+ for ATP when the ATP is hydrolyzed while in comparison, respiration 
based ATP production is pH neutral when the ATP is consumed. 
By integrating all the above results, we predict that glycolytic ATP biosynthesis is a cellular response 
to the persistent OH- production by cytosolic Fenton reactions across all 14 cancer types. 
One puzzling issue remains: why do cancer cells secrete lactic acids (lactate + proton) when they 
face a major challenge to keep the intracellular pH from becoming too alkaline to remain viable? To 
address this issue, we have conducted correlation analyses between the expression levels of SLC16A1 
and all the up-regulated genes in each cancer type, followed by pathway-enrichment analyses of these 
genes. We have then examined the 100 most enriched pathways in each cancer type. We find that the 
most enriched pathways are involved in the biological processes related to immune system, cell cycle, 
and response to stress (Figure 4), hence suggesting that the secretion of the lactic acid might be 
regulated by external signals. This observation is consistent with previous studies suggesting that 
expression of SLC16A1 is regulated by hypoxia [32], hyaluronic acid receptor CD44 [33], and local 
stromal cells [33] in cancer. 
Previous studies have suggested that lactic acids might serve protective roles in cancer against 
attacks by T cells [34]. Therefore, we conclude that lactic acid secretion by SLC16A1 is most likely not 
related to intracellular pH homeostasis, instead it serves a protective role for cancer.  
Glycolytic ATP synthesis maintains the elevated intracellular pH during NPC proliferation 
To understand the functional roles of glycolytic ATP production followed by lactic acid secretion in NPCs, 
we have performed correlation analyses between the expressions of PKM and genes related to the 
predicted cytosolic Fenton reaction on the NPC data. The analyses revealed that unlike cancer cells, no 
or very little correlation between expressions of glycolytic ATP production (PKM gene) and the Fenton 
reaction-defining genes, namely proteasome, iron uptake, and H2O2 genes in NPCs, as shown in Figure 
S3, hence suggesting that the reason for glycolytic ATP production in NPCs is different from that in 
cancers. 
  
To probe why NPCs utilize glycolysis to produce ATP during their proliferating phase, we first review 
how unicellular organisms such as E. coli and yeast control their cell cycle. It has been well established 
that in E. coli, nutrients are first used towards ATP production via the respiration process. This process 
switches largely to nucleotide and nucleotide-sugar syntheses once the cellular ATP concentration rises 
to a certain level, as result of that ATP production rate is higher than that of ATP consumption. Clearly, 
this will lead to increased cellular concentrations of nucleotides and nucleotide-sugar. It has been 
established that the cellular nucleotide-sugar concentration serves as the cue for cell cycle progression 
in E. coli [35] and Bacillus subtilis [36]. Hence when the cell cycle starts, the cells already have 
substantial levels of ATP accumulated needed for cell division.
The accumulation of the respiration-synthesized ATP also leads to an increase in the intracellular pH, 
as needed for the proliferation phase [37]. The reason is that respiration-based ATP biosynthesis 
consumes one proton per ATP, hence driving the pH up when the ATPs are accumulated. Since cell 
proliferation requires an elevated intracellular pH (from 6.8 to 7.2−7.4 [38]), cells must alter its way of 
ATP synthesis as otherwise the consumption of each ATP will release one H+, hence decreasing the pH. 
We predict that this is the reason that NPCs switch to glycolytic ATP production when cell proliferation 
starts. Details follow. Recall that the synthesis of each glycolytic ATP is pH neutral and produces on 
lactate [39]. When the respiration based ATP is consumed for cell proliferation, one H+ is generated. 
Now cells release this proton along with the lactate in the form of lactic acid. This serves two purposes: 
(1) maintaining the intracellular pH and (2) replenishing the consumed ATP. Again, it is worthy 
reemphasizing that the proton released along with lactate is NOT from glycolysis, instead, from 
hydrolysis of an ATP previously generated by respiration. 
While this has not been demonstrated for normal human proliferating cells, we hypothesize that 
they basically follow a similar process to maintain a pH level needed for cell proliferation through 
glycolytic ATP production followed by lactic acid secretion. To provide supporting evidence, we have 
conducted a co-expression analysis between SLC16A1 and all the up-regulated genes in each set of NPC 
samples, followed by pathway enrichment analyses. We find that majority of the enriched pathways are 
growth or development related. Moreover, over two thirds of the pathways that are most commonly 
shared by different NPCs are also growth or development related (Table S8), hence suggesting our 
prediction that the cellular roles of SLC16A1 is different in cancer and in NPCs.
While we do not have experimental data to directly support the prediction that increased 
intracellular pH is essential to human cell proliferation, there are data that indirectly support our 
  
prediction. Specifically, we have analyzed a gene expression dataset (GSE77239) that was generated in 
an study aimed to examine the effect of inhibiting an acid-extruding pump in endothelial cells [40]. We 
have found that the expression levels of cell proliferation and glycolytic genes were reduced when the 
cells were treated by the inhibitor of the pump (Table S9).
We have also studied the time-course data in one of the NPC datasets, GSE11292 for regulatory T 
cells and effector T cells. The dataset contains gene-expression data of the cells collected every 20 min 
at 19 time points starting from time zero. We have specifically examined genes involved in the 
respiratory chain, glycolysis, lactic acid secretion, and the gene, PRKAA1, involved in AMP degradation, 
whose expression level is known to be proportional to the intracellular ATP level [41], as shown in Figure 
5. We find that the expression levels of the respiratory chain genes decrease continuously while the 
expressions of glycolytic ATP synthesis genes increase. In the meantime, the intracellular ATP 
concentration with the expression of PRKAA1 as a readout reaches and stays at a high level and then 
gradually goes down starting at time T3 This observation is consistent with our model, namely, that (i) 
cell proliferation starts at a point when the intracellular ATP concentration reaches a high level; and (ii) 
the cells increase glycolytic ATP production and reduces respiration-based ATP synthesis during 
proliferation. Highly similar patterns are observed in other similar cases, as detailed in Figure S4.
It is noteworthy that unlike E. coli, respiratory ATPs are generated in mitochondria rather than in 
cytosol. Since cytosolic proton movement into mitochondria via the ATP synthase (or UCP transporters) 
is driven by proton gradient [42], we postulate that the increased mitochondrial pH would lead to 
increased cytosolic pH. 
To estimate the number of respiratory ATPs that need to be accumulated to raise the intracellular 
pH from 6.8 to 7.4 (pH value needed for cell proliferation) in a normal human cell, we have calculated 
the number of protons needed to make such a change. Here we assume that the volume of the cell is 
100 μm3, based on human cell data [43]. For the intracellular pH to change from 6.8 to 7.4, the 
concentration of the H+ needs to change from 10-6.8 to 10-7.4. Assuming that the pH buffering coefficient 
of the cell is  for this pH range [44], the number of protons needed to make such a change is 2 ×  105
calculated as, (10 ‒ 6.8 ‒  10 ‒ 7.4) ×  100 ×  2 ×  105 ×  10 ‒ 15 ×  6.02 ×  1023≅1.43 ×  109
  
where  is the Asogadro constant. Hence, it takes approximately  protons, 6.02 ×  1023 1.43 ×  109
hence this number of ATPs to make the desired pH change. Knowing that there are ~6 ×  109
nucleotides in human genome and it takes approximately five ATPs to synthesize one nucleotide on 
average, we predict that a cell must accumulate at least the number of ATPs needed to synthesize ~4.7% 
(143/3000) of a human DNA to raise the pH from 6.8 to 7.4. 
Figure 6 summarizes the key differences between the Warburg effects in cancer cells vs. NPCs. 
Based on all the analyses, we predict that while both normal proliferating cells and cancer cells have the 
Warburg effect, they do it for fundamentally different reasons.
Discussion
Several papers suggest that the Warburg effect is a common characteristic of all proliferating cells, 
including cancer and normal proliferating cells. Our comparative analyses of gene expression data 
between cancer tissue cells and NPCs provide strong evidence that they do this for fundamentally 
different reasons. Specifically, cancer cells do this mainly to produce net protons for neutralizing OH- 
that is generated persistently by cytosolic Fenton reactions, whereas NPCs do this to maintain the 
elevated cytosolic pH needed for the optimal performance of the ribosomal proteins [37]. Moreover, 
cancer cells secrete lactic acids largely independent of lactate generation and they do this probably for 
protecting cancer cells from destruction by immune cells. 
To avoid possible noises introduced by non-cancerous cells, we have selected in our analyses 
cancer tissue samples that are predicted to contain cancer cells with high purity. However, the results 
derived using such samples are essentially the same with the results derived from all samples of the 14 
caner types in TCGA without this selection. 
While our analyses provide generally consistent results across the 14 cancer types, we notice that 
kidney cancers tend to show different characteristics in maintaining their cytosolic acid-base 
homeostasis from other cancers, suggesting that further studies are needed. 
We have also examined the protein abundances of the up-regulated genes in our model in the 
relevant cancer types (when available) from the Human Protein Atlas, and found that virtually all the 
highly up-regulated genes also have significant increase in protein abundance in the same cancer types 
  
if such data are available, hence indicating that our gene-expression based analyses are as valid as 
protein abundance based analyses if they were available.
Overall, the discovery made in this study offers a novel angle to examine cancer from the 
perspective of acid-base homeostasis. Our unique way in connecting coarse-grained information derived 
from gene-expression data with detailed chemistry properties of cells such as pH may offer a novel 
approach to tackle complex diseases like cancer, hence potentially leading to deeper understanding 
about cancer formation and development. 
Materials and methods
Data processing and normalization
We have used RNA-seq data of 1612 samples covering 14 cancer types from the TCGA database [45], 
each having at least 13 cancer and (not necessarily paired) control samples, with gene expression levels 
indicated using normalized FPKM (with log2 transformation). 
The purity of cancer tissue samples was predicted using five programs, namely ESTIMATE, 
ABSOLUTE, LUMP, IHC, and CPE [46]. Cancer tissue samples with the highest purity for each cancer type 
were selected, based on consensus results by the five methods. The detailed information about how 
tissue purity is assessed is given in File S1. 
In addition, 143 samples of five NPC types with microarray-based gene expression data were 
selected from the GEO [47]. These include activated CD4+ T cells (GSE60235, GPL570) [48], induced 
pluripotent stem cell (GSE25970, GPL3921) [49], re-epithelialization cells (GSE28914, GPL570) [50], 
activated regulatory T cells (GSE11292, GPL570), and activated effector T cell (GSE11292) [51]. Each 
dataset consists of gene-expression data for both activated and inactive cell, used as controls. These 
cells are good representatives among proliferating noncancerous human cells, with the related datasets 
representing good qualities among all the relevant datasets in GEO. For a gene with multiple probes, we 
chose the probe having the highest average expression level to represent its expression. MAS5 in the R 
package “affy” [52] was used to normalize the gene expression data.
Table 1 summarizes the sample information for both cancer and NPC data used in this study. The 
original information of the cancer samples collected from TCGA before selection is given in Table S10 
and Figure S5. 
  
The expression levels of all genes in all cancer samples of each type form a bimodal distribution 
(Figure S6), where the first peak (from left to right) represents genes that are not expressed and the 
second peak is for the expressed genes. For each cancer type, genes with expression values lower than 
or equal to the lowest point of the valley between the two peaks is considered as not expressed. The 
same criteria apply to the controls as well as the NPC samples from GEO. 
Selection of pH-related transporter genes
We examined all the genes in the transporter families, including bicarbonate transporters, sodium-
proton exchangers, anion exchangers, V-ATPase, lactic acid transporters, Ca2+-ATPase, and K+/H+ ATPase. 
A few transporters localized in plasma membrane were considered as reliable acid-loading or acid-
extruding transporters. Details follow.
The family of bicarbonate-transporter genes consists of eleven SLC4 genes. SLC4A1, 2, 3 are 
known to exchange extracellular Cl- for intracellular HCO- [53], hence serving as acid loaders; 
and SLC4A4-10 tend to cotransport extracellular Na+ and HCO3- into cells [54], hence acid 
extruders. It is known that SLC4A11 does not transport bicarbonate, hence not considered; and 
SLC4A6 has not been identified yet. Out of the remaining ones, SLC4A8 and A10 are not 
expressed in any samples, cancer or control. SLC4A1 and SLC4A5 are each expressed in only 
one tissue type: 4A1 in kidney and 4A5 in thyroid. SLC4A7 tends to be located in focal adhesion 
sites, in addition to plasma membrane, making their interpretation challenging. Hence, we do not 
consider any of these SLC4 transporters, which leaves SLC4A1AP (an adaptor protein of 
SLC4A1), A2, A3 as acid loaders, and SLC4A4 and A9 as acid extruders.  
The family of sodium-proton exchangers consists of nine SLC9A genes, which generally 
exchange extracellular Na+ for intracellular H+ (or NH4+), hence acid extruders [55]. The 
following five SLC9A genes are not considered for different reasons in our study. SLC9A1 and 
A7 can be localized to at least three subcellular compartments [56]. SLC9A8 is localized only in 
Golgi. SLC9A5 is not expressed in any samples studied here. SLC9A6 is predominantly 
expressed in endosome [57]. This leaves SLC9A2, 3, 4, 9 for further analyses. 
Among the SLC26 anion exchangers, only six may exchange Cl- for HCO3-, namely 
SLC26A3−4, 6−7, 9, 11 [58]. SLC26A3 and A4 are not expressed in majority of the tissue types 
under study, hence not considered. SLC26A7 is mainly a chloride channel, which exchanges Cl- 
  
for a range of intracellular anions [59], hence not considered. SLC26A11 can be localized to five 
subcellular compartments, hence too non-specific and not considered. This leaves two genes in 
our study: SLC26A6 and A9. Interestingly, while both transporters exchange Cl- for an anion, 
including HCO3-, they facilitate Cl- flux in the opposite directions, namely SLC26A6 moving 
extracellular Cl- into cells [60] and A9 moving intracellular Cl- out [61]. 
The ATP6V genes encoding the V-ATPase complex tend to have multiple subcellular 
locations. Considering that only those localized to plasma membrane are relevant to our study, 
we have developed a computational method to de-convolute the observed expressions of the 
ATP6V genes to tease out the portions of these genes whose protein products are localized in the 
plasma membrane (see File S1). Table S2 lists the estimated average expression levels of the 
ATP6V genes whose protein products are localized in plasma membrane across different cell 
types. 
Both lactic acid transporter genes, SLC16A1 and A3, are included in our analyses. Neither the 
Ca2+-ATPase (encoded by the ATP2B1-4 genes) nor the K+/H+ ATPase (encoded by the ATP4A, 
B genes) is particularly informative, hence we did not include them in our analyses.
Calculation of correlation and statistical significance 
To calculate the correlation between the expression of a given gene g and a set of M genes in a sample 
set, we choose the first two principle components (PCs) to represent the gene set if they can explain at 
least 75% of the data variance. A linear regression model was constructed as shown below.
  (1)𝑒(g) ~ 𝛽1𝑃𝐶1 + 𝛽2𝑃𝐶2 + 𝛽0
where  is the expression of gene ;  and  are the first and second PCs of the expression of  𝑒(g) g 𝑃𝐶1 𝑃𝐶2
the gene set in the given samples; and {  are regression parameters. If  and  fail to explain at 𝛽𝑖} 𝑃𝐶1 𝑃𝐶2
least 75% of the data variance, we use the following procedure to assess the statistical significance of 
the detected correlation between the gene g and the set of M genes. First, we calculate the Pearson 
correlations between g and each of the N genes in the human genome (N = 20,000) as the background; 
and then we conduct a multiple-hypothesis test using the false discovery rate control, to select n genes 
from N to achieve statistical significance for each correlation with g (P < 0.01). The P value for the 
correlation is calculated as: 
  
   (2)𝑃 = 1 ‒ ∑𝑚 ‒ 1𝑖 = 0 (𝑀𝑖 )(𝑁 ‒ 𝑀𝑛 ‒ 𝑖 )(𝑁𝑛)
where m is the number of genes in the union of the n- and M- gene sets. For two gene sets GS1 
and GS2 and their gene expression matrices M1 and M2 (across samples), we first calculate their 
principal curves [62] to capture the nonlinear variance within matrices M1 and M2. We then 
project each sample of M1 or M2 onto the corresponding principal curve, denoted as DP1 and 
DP2, respectively. Pearson’s correlation coefficient (PCC) between DP1 and DP2 is then 
calculated to indicate the correlation between the two gene sets and the relevant p-value. R 
package “pathifier” was applied to calculate the principal curve of the gene expression matrix.
Identification of differentially-expressed genes
We have applied Wilcoxon signed-rank test for cancer samples vs. matching controls and NPCs vs. 
controls to identify differentially- expressed genes (DEGs). A gene is considered to be significantly 
differentially expressed if the difference in its expression is at least 1.3 fold between cancer (or NPCs) 
and their relevant control samples (FC > 1.3), with the false discovery rate < 0.01.
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Figure legends
Figure 1  Heatmaps for differential expressions of the selected transporter genes
The first zone is for acid-loading transporters, the second for acid-extruding transporters, and the last 
for lactate acid extruding transporters. Gene expression levels are indicated with FPKM presented as 
log2FC, with log2FC > 0.6 for up-regulated genes and log2FC < −0.6 for down-regulated genes. FC, fold 
change.
Figure 2  Co-expression of proteasome(PSM) genes and acid-loading or acid-extruding transporter 
genes in 14 cancer types and NPCs
Co-expression was measured using Pearson correlation coefficient. The positive and negative 
correlations are indicated in green and black, respectively, with the size of each square representing the 
correlation level. Proteasome genes is given in Table S6.
Figure 3  Correlations between Fenton reaction level and ATP production genes
A. Correlation between PKM and one acid-loading and two acid-extruding transporter genes: SLC4A3, 
SLC4A4, and SLC9A9, SLC16A1, and SLC16A3. “-” represents the lack of the significant correlation. B. 
  
Pearson correlation between glycolytic ATP production genes (PKM and PGK1) and genes reflecting the 
levels of cytosolic Fenton reactions (proteasome genes, iron uptake genes and H2O2 related genes in 
Table S6) in cancer.
Figure 4  The most commonly enriched pathways by genes strongly correlated with SLC16A1 across 
the 14 cancer types
The length of a bar represents the number of cancer types where the pathway is enriched with genes 
whose expression strongly correlates with the expression of SLC16A1. 
Figure 5  Time-specific expression data of key genes involved in Warburg effect, electron transport 
chain and nucleotide synthesis pathways in GSE11292 
The left panel shows the expression levels of PKM, SLC16A1, NDUFS2, SDHD, UQCRFS1, and COX10, four 
representative genes for electron transport chain Complex I, II, III and IV, respectively, where the time 
course data with 18 time points are grouped into six segments with each containing three consecutive 
points and Ti represents the ith segment, 0 ≤ i ≤ 5. The right panel shows the expression levels of PPAT, 
GART, PRPS2, and HPRT1 (blue), key genes in nucleotide synthesis pathways, as well as the expression 
level of PRKAA. 
Figure 6  Schematic illustration of the key differences between the Warburg effects in cancer cells vs. 
NPCs
A. Warburg effects in cancer. B. Warburg effects in normal proliferating cells. 
Tables 
Table 1  Samples of cancer tissues of 14 types and of five NPC types used in our study after purity 
selection
  
Supplementary material
File S1  Data and methods
Figure S1  Boxplots represent gene expression levels of Warburg effect related genes across different 
stages of the 13 cancer types
Gene expression levels of Warburg effect related genes SLC16A1/3, LDHA, PKM, and PDHB 
against PKM, across 13 cancer types: n is for control, s1 is for stage 1, s2 is for stage 2, s3 is for 
stage 3 and s4 is for stage 4 from left to right. The stage information of prostate cancer in TCGA 
is not available, hence prostate cancer is not included in the analysis. 
Figure S2  Boxplots represent gene expression levels of Warburg effect related genes in five NPC: 
control and activated 
Gene expression levels of Warburg effect related genes SLC16A1/3, LDHA, PKM, and PDHB against PKM 
across five NPC in control and activated.
 
Figure S3  Pearson correlations between PKM and genes used in Figure 3 in five NPCs 
(1) Proteasome genes, (2) iron uptake genes, (3) SLC16A1/3, and (4) H2O2 related genes. 
Figure S4  Time-specific expression data of key genes involved in Warburg effect, electron transport 
chain and nucleotide synthesis pathways and expression level of PRKAA in GSE60234
Gene expression levels of PKM, SLC16A1(Warburg effect), COX7A1 (electron transport chain), PPAT, 
GART (nucleotide synthesis), and expression level of PRKAA where the time course data with 8 time 
points are grouped into 4 segments with each containing 2 consecutive points and Ti represents the ith 
segment, 0 ≤ i ≤ 4. 
Figure S5  Percentages of cancer samples in different stages 
  
A. Before purity-based selection. B. After purity-based selection. The purity-based selection was 
not performed for ESCA and STAD, due to the incompatibility of the data formats. 
Figure S6  Gene expression density distributions for each cancer type and each NPC type 
A. Expression density distributions for each cancer type, one for cancer samples and one for controls. B. 
Expression density distributions for each NPC type, one for activated samples and one for controls. RNA-
seq data for ESCA and STAD were generated using Illumina HiSeq v1, and all other cancer data examined 
here were generated using Illumina HiSeq v2.
Table S1  Subcellular locations for the ATP6V genes
Subcellular locations predicted with confidence scores 4 or 5 by Genecards [18]are listed in the second 
column and additional ones, if any, with score 3 are listed in the third column.
Table S2  Average expression levels of the ATP6V genes contributed by those located in plasma 
membrane 
A. Expression levels are indicated with FPKM in cancer. B. Expression levels are indicated with 
normalized microarray data in NPCs. 
Table S3  Statistical correlation between the two sides of the Michaelis-Menten equation based 
Fenton reactions
R2 values for the statistical correlation between the two sides of the Michaelis-Menten equation based 
Fenton reactions along with the associated statistical significance of the R2 value. We have then 
conducted 10,000 permutations of the two sides genes. Let N be such R2 value and M the number of 
times out of these permutation tests with significant gene pairs at least being N. The M/100,000 is used 
as the significance value.
Table S4  Number of up-regulated proteasome genes in cancer and NPCs
  
Table S5  Pathways enriched by genes whose expressions correlate positively with acid-loading 
transporters and negatively with acid-extruding ones in cancer (redundant pathways have been 
removed) 
Table S6  Genes used to estimate the occurrence of cytosolic Fenton reaction
Table S7  Correlation and statistic confidence between proteasome genes and acid-loading & 
extruding transporter genes of the 14 cancer types and NPCs
Proteasome genes are given in Table S6, acid-loading and extruding transporter genes are the same with 
gene list in Figure 1.
Table S8  Pathways enriched by genes strongly correlated with SLC16A1 (or SLC16A3 if SLC16A1 is not 
available) in NPCs
We define it strongly correlated if the statistical significance of Pearson correlation below 0.005.
Table S9  Differential expressions of the selected cell proliferation and Warburg effect related genes in 
GSE77239
Table S10  Samples of cancer tissues of 14 types in the TCGA database before purity selection
  
  
  
  
  
  
  
Table 1  Samples of cancer tissues of 14 types and of five NPC types
 Type
No. of 
cancer/activated 
samples
No. of  
control 
samples
Bladder urothelial carcinoma (BLCA) 94 19
Breast invasive carcinoma (BRCA) 153 113
Colon adenocarcinoma (COAD) 55 41
Esophageal carcinoma (ESCA) 184* 13
Head and Neck squamous cell carcinoma (HNSC) 79 44
Kidney chromophobe (KICH) 34 25
Kidney renal clear cell carcinoma (KIRC) 91 72
Kidney renal papillary cell carcinoma (KIRP) 38 32
Liver hepatocellular carcinoma (LIHC) 65 50
Lung adenocarcinoma (LUAD) 92 59
Lung squamous cell carcinoma (LUSC) 59 51
Prostate adenocarcinoma (PRAD) 133 52
Stomach adenocarcinoma (STAD) 238* 33
Thyroid carcinoma (THCA) 56 59
Activated CD4+ T cells (GSE60235) 15 15
Activated effector T cells (GSE11292) 32 6
Activated regulatory T cells (GSE11292)  32 6
Induced pluripotent stem cell (GSE25970) 12 6
Re-epithelizing skin cells (GSE28914) 11 8
Note: * represents a case where all the cancer samples of the cancer type in TCGA are 
used instead those with predicted high purity since some of the programs do not apply to 
the data format of the cancer type.
